Business
CTA application to MHRA and Corporate Update
CTA application to MHRA and Corporate Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \n \n Sareum Holdings PLC\n \n \n (\"Sareum\" or the \"Company\")\n \n \n \n Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update\n \n \n \n á\n Clinical Trial Authorisation application for a Phase 1a/b clinical trial with SDC-1801 submitted to the UK Medicines and Healthcare Products Regulatory Agency\n \n \n á\n Sareum has made significant progress advancing SDC-1801 towards clinical development and plans to initiate Phase 1 clinical trials in\n 2022, with a study in psoriasis targeted for 2023\n \n \n á\n The Company continues to progress translational studies to support its cancer immunotherapy candidate, SDC-1802\n \n \n á\n New EU patent granted (April 2022), protecting the SDC-1802 molecule and pharmaceutical preparations as a therapeutic to treat T-cell acute lymphoblastic leukaemia\n \n \n á\n Sareum had a cash position of approximately £4.3 million as at 30 June 2022\n \n \n á\n A presentation to investors will take place on 4 August 2022 at 10.00am via the Investor Meet Company platform. See below for registration details.\n \n \n \n \n \n \n \n \n Cambridge, UK, 28 July 2022\n \n Ð Sareum Holdings plc (AIM: SAR), the specialist drug development company, today announces that it has submitted an application for a Clinical Trial Authorisation (\"CTA\") to the UK Medicines and Healthcare Products Regulatory Agency (\"MHRA\") for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis.\n \n \n Sareum also provides a broader update on operational activities and pipeline progress.\n \n \n \n OPERATIONAL HIGHLIGHTS -\n \n \n STRONG PIPELINE PROGRESS\n \n \n \n \n SDC-1801 (autoimmune disease)\n \n \n \n SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.\n \n \n \n \n \n Preclinical development activities required to apply for the CTA have been successfully concluded and, consistent with the Company's clinical development plan, an application for a CTA has now been filed.\n \n \n \n \n \n TYK2/JAK1 inhibition has demonstrated benefits in maintaining a healthy immune system and has strong clinical validati...